Literature DB >> 20810916

Plasma gelsolin modulates cellular response to sphingosine 1-phosphate.

Robert Bucki1, Alina Kulakowska, Fitzroy J Byfield, Malgorzata Zendzian-Piotrowska, Marcin Baranowski, Michal Marzec, Jessamine P Winer, Nicholas J Ciccarelli, Jan Górski, Wieslaw Drozdowski, Robert Bittman, Paul A Janmey.   

Abstract

Hypogelsolinemia is observed in patients with different states of acute or chronic inflammation such as sepsis, rheumatoid arthritis, and multiple sclerosis. In animal models of sepsis, repletion of plasma gelsolin reduces septic mortality. However, the functions of extracellular gelsolin and the mechanisms leading to its protective nature are poorly understood. Potential mechanisms involve gelsolin's extracellular actin scavenging function or its ability to bind bioactive lipids or proinflammatory mediators, which would limit inflammatory responses and prevent tissue damage. Here we report that human plasma gelsolin binds to sphingosine 1-phosphate (S1P), a pleiotropic cellular agonist involved in various immune responses, and to its synthetic structural analog FTY720P (Gilenya). The fluorescence intensity of a rhodamine B-labeled phosphatidylinositol 4,5-bisphosphate binding peptide derived from gelsolin and the optical density of recombinant human plasma gelsolin (rhpGSN) were found to decrease after the addition of S1P or FTY720P. Gelsolin's ability to depolymerize F-actin also decreased progressively with increasing addition of S1P. Transient increases in phosphorylation of extracellular signal-regulated kinase in bovine aortic endothelial cells (BAECs) after S1P treatment were inhibited by rhpGSN. The ability of S1P to increase F-actin content and the elastic modulus of primary astrocytes and BAECs was also prevented by rhpGSN. Evaluation of S1P and gelsolin levels in cerebrospinal fluid reveals a low concentration of gelsolin and a high concentration of S1P in samples obtained from patients suffering from lymphatic meningitis. These findings suggest that gelsolin-mediated regulation of S1P bioactivity may be important to maintain immunomodulatory balance at inflammatory sites.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20810916      PMCID: PMC3006327          DOI: 10.1152/ajpcell.00051.2010

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  50 in total

1.  Bone marrow-derived human mesenchymal stem cells become quiescent on soft substrates but remain responsive to chemical or mechanical stimuli.

Authors:  Jessamine P Winer; Paul A Janmey; Margaret E McCormick; Makoto Funaki
Journal:  Tissue Eng Part A       Date:  2009-01       Impact factor: 3.845

2.  Extracellular gelsolin binds lipoteichoic acid and modulates cellular response to proinflammatory bacterial wall components.

Authors:  Robert Bucki; Fitzroy J Byfield; Alina Kulakowska; Margaret E McCormick; Wieslaw Drozdowski; Zbigniew Namiot; Thomas Hartung; Paul A Janmey
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

3.  Simultaneous quantitative analysis of sphingoid base 1-phosphates in biological samples by o-phthalaldehyde precolumn derivatization after dephosphorylation with alkaline phosphatase.

Authors:  Jung-Kee Min; Hwan-Soo Yoo; Eun-Young Lee; Woo-Jin Lee; Yong-Moon Lee
Journal:  Anal Biochem       Date:  2002-04-15       Impact factor: 3.365

Review 4.  Plasma gelsolin: function, prognostic value, and potential therapeutic use.

Authors:  Robert Bucki; Ilya Levental; Alina Kulakowska; Paul A Janmey
Journal:  Curr Protein Pept Sci       Date:  2008-12       Impact factor: 3.272

5.  Determination of phosphoinositide binding to K(+) channel subunits using a protein-lipid overlay assay.

Authors:  Alison M Thomas; Andrew Tinker
Journal:  Methods Mol Biol       Date:  2008

6.  Gelsolin concentration in cerebrospinal fluid from patients with multiple sclerosis and other neurological disorders.

Authors:  A Kulakowska; W Drozdowski; A Sadzynski; R Bucki; P A Janmey
Journal:  Eur J Neurol       Date:  2008-06       Impact factor: 6.089

7.  pH dependence of sphingosine aggregation.

Authors:  Hirotaka Sasaki; Hiromi Arai; Melanie J Cocco; Stephen H White
Journal:  Biophys J       Date:  2009-04-08       Impact factor: 4.033

8.  Gelsolin down-regulates lipopolysaccharide-induced intraamniotic tumor necrosis factor-alpha production in the midtrimester of pregnancy.

Authors:  Devrim Sezen; Ann Marie Bongiovanni; Shari Gelber; Uma Perni; J Milton Hutson; Daniel Skupski; Steven S Witkin
Journal:  Am J Obstet Gynecol       Date:  2008-12-25       Impact factor: 8.661

9.  Decreased levels of the gelsolin plasma isoform in patients with rheumatoid arthritis.

Authors:  Teresia M Osborn; Margareta Verdrengh; Thomas P Stossel; Andrej Tarkowski; Maria Bokarewa
Journal:  Arthritis Res Ther       Date:  2008-09-27       Impact factor: 5.156

10.  Plasma gelsolin depletion and circulating actin in sepsis: a pilot study.

Authors:  Po-Shun Lee; Sanjay R Patel; David C Christiani; Ednan Bajwa; Thomas P Stossel; Aaron B Waxman
Journal:  PLoS One       Date:  2008-11-12       Impact factor: 3.240

View more
  28 in total

1.  Depletion of plasma gelsolin in patients with tick-borne encephalitis and Lyme neuroborreliosis.

Authors:  Alina Kułakowska; Joanna M Zajkowska; Nicholas J Ciccarelli; Barbara Mroczko; Wiesław Drozdowski; Robert Bucki
Journal:  Neurodegener Dis       Date:  2011-03-10       Impact factor: 2.977

Review 2.  Gelsolin amyloidosis: genetics, biochemistry, pathology and possible strategies for therapeutic intervention.

Authors:  James P Solomon; Lesley J Page; William E Balch; Jeffery W Kelly
Journal:  Crit Rev Biochem Mol Biol       Date:  2012-02-24       Impact factor: 8.250

3.  Maternal serum proteome changes between the first and third trimester of pregnancy in rural southern Nepal.

Authors:  P F Scholl; R N Cole; I Ruczinski; M Gucek; R Diez; A Rennie; C Nathasingh; K Schulze; P Christian; J D Yager; J D Groopman; K P West
Journal:  Placenta       Date:  2012-03-03       Impact factor: 3.481

4.  Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Penicillin-Susceptible and Penicillin-Resistant Pneumococcal Pneumonia.

Authors:  Zhiping Yang; Alice Bedugnis; Susan Levinson; Mark Dinubile; Thomas Stossel; Quan Lu; Lester Kobzik
Journal:  J Infect Dis       Date:  2019-09-26       Impact factor: 5.226

Review 5.  Crosstalk between sphingolipids and vitamin D3: potential role in the nervous system.

Authors:  Mercedes Garcia-Gil; Federica Pierucci; Ambra Vestri; Elisabetta Meacci
Journal:  Br J Pharmacol       Date:  2017-02-24       Impact factor: 8.739

6.  Safety and Pharmacokinetics of Recombinant Human Plasma Gelsolin in Patients Hospitalized for Nonsevere Community-Acquired Pneumonia.

Authors:  Abla Tannous; Susan L Levinson; James Bolognese; Steven M Opal; Mark J DiNubile
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

7.  Vitamin D therapy in experimental allergic encephalomyelitis could be limited by opposing effects of sphingosine 1-phosphate and gelsolin dysregulation.

Authors:  Yanyan Zhu; Zhaoyu Qin; Jifang Gao; Mingchong Yang; Yanjiang Qin; Ting Shen; Shilian Liu
Journal:  Mol Neurobiol       Date:  2014-04-11       Impact factor: 5.590

8.  Recruitment of sphingosine kinase to presynaptic terminals by a conserved muscarinic signaling pathway promotes neurotransmitter release.

Authors:  Jason P Chan; Zhitao Hu; Derek Sieburth
Journal:  Genes Dev       Date:  2012-05-15       Impact factor: 11.361

9.  Plasma gelsolin improves lung host defense against pneumonia by enhancing macrophage NOS3 function.

Authors:  Zhiping Yang; Terry Ting-Yu Chiou; Thomas P Stossel; Lester Kobzik
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-05-08       Impact factor: 5.464

10.  Low Admission Plasma Gelsolin Concentrations Identify Community-acquired Pneumonia Patients at High Risk for Severe Outcomes.

Authors:  Wesley H Self; Richard G Wunderink; Mark J DiNubile; Thomas P Stossel; Susan L Levinson; Derek J Williams; Evan J Anderson; Anna M Bramley; Seema Jain; Kathryn M Edwards; Carlos G Grijalva
Journal:  Clin Infect Dis       Date:  2019-09-13       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.